Bosutinib - Chronic Myeloid Leukemia
Bosutinib is a third generation tyrosine kinase inhibitor.
Sites
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
April 12, 2012, PublMed
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
April 12, 2012, PublMed
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ CML
January 29, 2012, Pfizer
Bosutinib Versus Imatinib (CML) Follow Up Study - Interview with Carlo Gambacorti-Passerini, MD, Professor of Internal Medicine VIDEO
December 2011,www.oncology.tv
Faster Response Rates in CML with Bosutinib
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia VIDEO
February 18, 2011, ecancerTV
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
Bosutinib in chronic-phase CML
October 13, 2010, The Leukemia and Lymphoma Society of Canada
Bosutinib May Have a Major Role in CML
September 2010, ASCO Post
Bosutinib effective as therapy in chronic myeloid leukemia
September 2, 2010, Pharminfo
STUDY 200: Study Evaluating bosutinib in Philadelphia Chromosome Positive Leukemias
June 4, 2010, Pfizer Oncology
January 29, 2012, Pfizer
Bosutinib Versus Imatinib (CML) Follow Up Study - Interview with Carlo Gambacorti-Passerini, MD, Professor of Internal Medicine VIDEO
December 2011,www.oncology.tv
Faster Response Rates in CML with Bosutinib
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia VIDEO
February 18, 2011, ecancerTV
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
Bosutinib in chronic-phase CML
October 13, 2010, The Leukemia and Lymphoma Society of Canada
Bosutinib May Have a Major Role in CML
September 2010, ASCO Post
Bosutinib effective as therapy in chronic myeloid leukemia
September 2, 2010, Pharminfo
STUDY 200: Study Evaluating bosutinib in Philadelphia Chromosome Positive Leukemias
June 4, 2010, Pfizer Oncology
.
